Press Releases

April 12, 2019

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb

April 12, 2019

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

March 29, 2019

Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation

March 29, 2019

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene

March 25, 2019

Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction;
Company Provides Additional Investor Materials

March 19, 2019

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

March 5, 2019

Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene

February 28, 2019

Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter

February 22, 2019

Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene

February 20, 2019

Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene

January 3, 2019

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company